Novel advanced and repurposed therapeutics for vision restoration in a group of severe rare ocular surface diseases: from validation to first clinical investigations

Información del proyecto

RESTORE VISION

Identificador del acuerdo de subvención: 101080611

DOI

10.3030/101080611

Fecha de la firma de la CE 6 Abril 2023

Fecha de inicio 1 Mayo 2023

Fecha de finalización 30 Abril 2027

Financiado con arreglo a

• Health

Coste total

€ 8 049 852,25

Aportación de la UE

€ 7 999 851,75

Coordinado por

UNIVERSITY OF GALWAY
Ireland

CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.

Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .

Resultado final

Data Management Plan (1)

First version of DMP

DMP will be prepared and updated throughout the project.

Websites, patent fillings, videos etc. (1)

Project Website

Public project website will be launched in Month 3 of the project. Partners and WP leads will be clearly stated on the website.

Publicaciones

Peer reviewed articles (12)

Excipients in drug delivery systems: A comprehensive review of approved inactive ingredients for human ophthalmic formulations

Autores: Raquel Gregorio Arribada, Daniela Rodrigues-Braz, Armando Silva-Cunha, Francine Behar-Cohen
Publicado en: European Journal of Pharmaceutics and Biopharmaceutics, Edición 208, 2025, ISSN 0939-6411
Editor: Elsevier BV
DOI: 10.1016/J.EJPB.2025.114637

A Novel Rat Model for Human Meibomian Gland Dysfunction and Ocular Rosacea

Autores: Linxin Zhu, Daniela Rodrigues-Braz, Emmanuelle Gélizé, Marine Crépin, Caroline Peltier, Coralie Lheure, Xavier Morel, Jean-Louis Bourges, Olivier Berdeaux, Francine Behar-Cohen, Min Zhao
Publicado en: Investigative Ophthalmology & Visual Science, Edición 67, 2026, ISSN 1552-5783
Editor: Association for Research in Vision and Ophthalmology (ARVO)
DOI: 10.1167/IOVS.67.1.14

Spironolactone Eyedrop Favors Restoration of Corneal Integrity after Wound Healing in the Rat

Autores: Daniela Rodrigues-Braz, Linxin Zhu, Emmanuelle Gélizé, Jean-Pierre Clarin, Xavier Chatagnon, Youcef Benzine, Philippe Rampignon, Agathe Thouvenin, Jean-Louis Bourges, Francine Behar-Cohen, Min Zhao
Publicado en: Pharmaceuticals, Edición 16, 2023, ISSN 1424-8247
Editor: MDPI AG
DOI: 10.3390/ph16101446

Central Corneal Epithelial Wounding Accelerates Aniridia-Associated Keratopathy in PAX6-Deficient Mice

Autores: Yedizza Rautavaara, Israa Sefawi, Meri Vattulainen, Petros Moustardas, Dina Javidjam, Ava Dashti, Neil Lagali
Publicado en: Investigative Ophthalmology & Visual Science, Edición 66, 2025, ISSN 1552-5783
Editor: Association for Research in Vision and Ophthalmology (ARVO)
DOI: 10.1167/IOVS.66.14.33

Selective, Temporary Postoperative Inhibition of Lymphangiogenesis by Integrin α5β1 Blockade Improves Allograft Survival in a Murine Model of High-Risk Corneal Transplantation

Autores: Tina Dietrich-Ntoukas, Felix Bock, Jasmine Onderka, Deniz Hos, Bjoern O. Bachmann, Grit Zahn, Claus Cursiefen
Publicado en: Journal of Clinical Medicine, Edición 13, 2024, ISSN 2077-0383
Editor: MDPI AG
DOI: 10.3390/jcm13154418

Transcriptomic Analysis in a Model of Aniridia-Associated Keratopathy for Target Discovery and Evaluation of Duloxetine Therapy

Autores: Dina Javidjam, Petros Moustardas, Ava Dashti, Daniel Aberdam, Arnaud Schweitzer-Chaput, Salvatore Cisternino, Dominique Bremond-Gignac, Neil Lagali
Publicado en: Investigative Ophthalmology & Visual Science, Edición 67, 2026, ISSN 1552-5783
Editor: Association for Research in Vision and Ophthalmology (ARVO)
DOI: 10.1167/IOVS.67.1.37

In-vitro immunomodulatory efficacy of extracellular vesicles derived from TGF-β1/IFN-γ dual licensed human bone marrow mesenchymal stromal cells

Autores: Jiemin Wang, Seyedmohammad Moosavizadeh, Manon Jammes, Abbas Tabasi, Trung Bach, Aideen E. Ryan, Thomas Ritter
Publicado en: Stem Cell Research & Therapy, Edición 16, 2025, ISSN 1757-6512
Editor: Springer Science and Business Media LLC
DOI: 10.1186/S13287-025-04476-2

Healing the Cornea: Exploring the Therapeutic Solutions Offered by MSCs and MSC-derived EVs

Autores: Manon Jammes, Abbas Tabasi, Trung Bach, Thomas Ritter
Publicado en: Progress in Retinal and Eye Research, 2024, ISSN 1350-9462
Editor: Elsevier BV
DOI: 10.1016/J.PRETEYERES.2024.101325

Mineralocorticoid receptor antagonism improves corneal integrity in a rat model of limbal stem cell deficiency

Autores: Daniela Rodrigues-Braz, Clémence Bonnet, Linxin Zhu, Nilufer Yesilirmak, Emmanuelle Gélizé, Laurent Jonet, Frédéric Jaisser, Jean-Louis Bourges, Francine Behar-Cohen, Min Zhao
Publicado en: Biomedicine & Pharmacotherapy, Edición 185, 2025, ISSN 0753-3322
Editor: Elsevier BV
DOI: 10.1016/J.BIOPHA.2025.117979

Cross-species transcriptomics identify mineralocorticoid receptor pathway overactivation as a central driver of ocular rosacea

Autores: Linxin Zhu, Nilufer Yesilirmak, Daniela Rodrigues-Braz, Emmanuelle Gélizé, Coralie Lheure, Xavier Morel, Jean-Louis Bourges, Frédéric Jaisser, Min ZHAO, Francine Behar-Cohen
Publicado en: Nature Communications, Edición 17, 2026, ISSN 2041-1723
Editor: Springer Science and Business Media LLC
DOI: 10.1038/S41467-026-71945-4

Comparison of in-vitro immunomodulatory capacity between large and small apoptotic bodies from human bone marrow mesenchymal stromal cells

Autores: Jiemin Wang, Seyedmohammad Moosavizadeh, Manon Jammes, Abbas Tabasi, Trung Bach, Aideen E. Ryan, Thomas Ritter
Publicado en: International Immunopharmacology, Edición 153, 2025, ISSN 1567-5769
Editor: Elsevier BV
DOI: 10.1016/J.INTIMP.2025.114480

Targeting insulin receptor substrate-1 delays disease progression in a murine model of aniridia-associated keratopathy

Autores: Ava Dashti, Petros Moustardas, Yedizza Rautavaara, Dina Javidjam, Israa Sefawi, Neil Lagali
Publicado en: Biomedicine & Pharmacotherapy, Edición 191, 2026, ISSN 0753-3322
Editor: Elsevier BV
DOI: 10.1016/J.BIOPHA.2025.118506